Ruthenium-97 DTPA: a new radiopharmaceutical for cisternography

J Nucl Med. 1981 Mar;22(3):269-73.


Ruthenium-97 DTPA (diethylenetriamine penta-acetic acid) was evaluated for its possible use as a cerebrospinal fluid imaging agent. Ru-97 has favorable physical properties that are highly suitable for imaging: decay by electron capture; gamma energy = 216 keV, 85%; T 1/2 = 2.9 days. Dogs were injected with 0.4 mCi Ru-97 DTPA or In-111 DTPA into the cisterna magna. The movement of the agents was monitored with a camera interfaced to a computer, or with a dual-probe system placed over the head and urinary bladder. In addition, blood and urine samples were collected at fixed intervals for 6 hr. High-quality images were obtained up to 48 hr after injection. The results show that the kinetics and excretion of Ru-97 DTPA are similar to those of In-111 DTPA. Radiation dose for identical activities is twice as high for In-111, in part because of greater abundance of the low-energy electron emission of In-111.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Brain / diagnostic imaging*
  • Cisterna Magna / diagnostic imaging*
  • Dogs
  • Drug Evaluation, Preclinical
  • Female
  • Hydrocephalus / diagnostic imaging
  • Indium / cerebrospinal fluid
  • Indium / metabolism
  • Mice
  • Pentetic Acid* / cerebrospinal fluid
  • Pentetic Acid* / metabolism
  • Radiation Dosage
  • Radioisotopes
  • Radionuclide Imaging
  • Ruthenium* / cerebrospinal fluid
  • Ruthenium* / metabolism
  • Time Factors
  • Tissue Distribution


  • Radioisotopes
  • Indium
  • Pentetic Acid
  • Ruthenium